Author

C. S. Walmsley

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

C. Chen· 1 shared C. E. Mills· 1 shared C. Liu· 1 shared D. Juric· 1 shared K. Subramanian· 1 shared M. Chung· 1 shared M. Hafner· 1 shared P. Sorger· 1 shared

Activity by Year

2019-2019 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

C. Chen

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and the potential for differential clinical activity

M. Hafner, C. E. Mills, K. Subramanian, C. Chen, M. Chung, S. A. Boswell, R. A. Everley, C. Liu, C. S. Walmsley, D. Juric, P. Sorger

This study compares the mechanisms of three FDA-approved CDK4/6 inhibitors and finds significant differences in their transcriptional, proteomic, and cellular effects, suggesting potential for differential clinical use.

bioRxiv · Mar 19, 2019Cancer Biology